Pharming Group (PHAR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$366.5M

Revenue (quarter)

$90.2M

Revenue growth (year over year)

−3.23%

Gross profit (trailing twelve months)

$317.1M

Gross margin

86.52%

Net income (trailing twelve months)

$9.3M

Net income (quarter)

$1.6M

Net income growth (year over year)

−64.00%

Net margin

2.54%

Return on equity

3.65%

EPS (trailing twelve months)

$0.14

Book value per share

$3.82

P/E (trailing twelve months)

73.36

Price to book

2.52

Debt to assets

42.20%

Payout ratio

—

Dividend yield

—

Company profile

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

• Is Pharming Group (PHAR) profitable?

  Yes. Pharming Group earned $9.3M in net income over the trailing twelve months, a net margin of 2.54%.

• How much revenue does Pharming Group (PHAR) make?

  Pharming Group generated $366.5M in revenue over the trailing twelve months, down 3.23% year over year.

• What is PHAR's P/E ratio?

  Pharming Group trades at 73.4 times trailing twelve-month earnings, on an EPS of $0.14.

• How do I buy stock in Pharming Group (PHAR)?

  PHAR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.